Cytotoxic T-lymphocytes recognizing P-glycoprotein in murine multidrug-resistant leukemias

European Journal of Haematology

Volumn 59, Issue 1, 1997, Pages 14-19

  Azuma, Eiichi ^a   Masuda, Shinichi ^a   Qi, Jiang ^a   Kumamoto, Tadashi ^a   Hirayama, Masahiro ^a   Nagai, Masataka ^a   Hiratake, Shinya ^a   Umemoto, Masakazu ^a   Komada, Yoshihiro ^a   Sakurai, Minoru ^a  

^a MIE UNIVERSITY   (Japan)

Author keywords

CTL; IL 4; P glycoprotein

Indexed keywords

DOXORUBICIN; GLYCOPROTEIN P; INTERLEUKIN 4;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; LEUKEMIA P 388; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

EID: 8544249094     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1997.tb00954.x     Document Type: Article

References (27)

1. KARTNER N, LING V. Multidrug resistance in cancer. Sci Am 1989: 260: 44-51.
2. FOXWELL BM, MACKIE A, LING V, RYFFEL B. Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein. Mol Pharmacol 1989: 36: 543-546.
3. RIVOLTINI L, COLOMBO MP, SUPINO R, BALLINARI D, TSURUO T, PARMIANI G. Modulation of multidrug resistance by verapamil or mdr1 anti-sense oligodeoxynucleotide does not change the high susceptibility to lymphokine-activated killers in mdr-resistant human carcinoma (LoVo) line. Int J Cancer 1990: 46: 727-732.
4. ARCECI RJ, STIEGLITZ K, BIERER BE. Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood 1992: 80: 1528-1536.
5. ARIYOSHI K, TSURUO T. Mouse-human chimeric antibody MH171 against the multidrug transporter P-glycoprotein. Jpn J Cancer Res 1992: 83: 515-518.
6. AZUMA E, HIRATAKE S, NISHIGUCHI Y. Successful abrogation of P-glycoprotein expression of a murine multidrug-resistant leukemia cell line with anti-sense multidrug mdr oligomer. Blood 1993: 82 (Suppl 1): 257a.
7. AZUMA E, HIRATAKE S, NISHIGUCHI Y. In vivo treatment of multidrug-resistant murine leukemia with antisense mdr1 oligodeoxynucleotides. Blood 1994: 84 (Suppl 1): 43a.
8. GREENBERG P, CHEEVER M, FEFER A. Eradication of desseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes. J Exp Med 1981: 154: 952-957.
9. + T cell lineage to mount an effective tumoricidal response to syngeneic tumor-bearing novel class I MHC antigens. J Immunol 1989: 143: 4287-4291.
10. FEARON ER, PARDOLL DM, ITAYA T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990: 60: 397-403.
11. PHILIPPS C, MCMILLAN M, FLOOD P, HS. Identification of a unique tumor-specific antigen as a novel class I major histocompatibility molecule. Proc Natl Acad Sci USA 1985: 82: 5140-5144.
12. STRAUSS J, R L, SCHREIBER H, GOODENOW R. Isolation of the MHC genes encoding the tumour-specific class I antigens expressed on a murine fibrosarcoma. J Immunogenet 1986: 13: 101-105.
13. INABA M, KOBAYASHI H, JOHNSON R. Active efflux of daunorubicin and Adriamycin in sensitive and resistant sublines of P388 leukemia. Cancer Res 1979: 39: 2200-2203.
14. IDO M, NAGAO Y, HIGASHIGAWA M, SAKURAI M. Differential growth inhibition of isoquinolinesulfonamides H-8 and H-7 towards multidrug-resistant P388 murine leukaemia cells. Br J Cancer 1991: 64: 1103-1107.
15. TAYLOR C, GROGAN T, SALMON S. Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms. Blood 1990: 75: 1114-1118.
16. KARTNER N, EVERNDEN-PORELLE D, LING V. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 1985: 316: 820-823.
17. TSURUO T, IIDA H, TSUKAGOSHI S, SAURAI Y. Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 1982: 47: 3460-3463.
18. AZUMA E, KAPLAN J. Role of lymphokine-activated killer cells as mediators of veto and natural suppression. J Immunol 1988: 141: 2601-2606.
19. AZUMA E, HANADA M, MASUDA S, KOMADA Y, SAKURAI M. Autologous tumor-specific cytotoxic T-lymphocytes in a child with neuroblastoma. Biomed Pharmacother 1990: 44: 487-493.
20. HUSSAIN R, NOURI A, OLIVER R. A new approach for measurement of cytotoxicity using colorimetric assay. J Immunol Methods 1993: 160: 89-96.
21. IWAHASHI T, OKOCHI E, TSURUO T, ONO K. Specific targeting and killing activities of anti-P-glycoprotein monoclonal antibody MRK16 directed against intrinsically multidrug-resistant human colorectal carcinoma cell lines in the nude mouse model. Cancer Res 1993: 53: 5475-5482.
22. DEFFIE AM, ALAM T, GOLDENBERG GJ. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glyco-protein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia. Cancer Res 1988: 48: 3595-3602.
23. EVANS CH, BAKER PD. Decreased P-glycoprotein expression in multidrug-sensitive and -resistant human myeloma cells induced by the cytokine leukoregulin. Cancer Res 1992: 52: 5893-5899.
24. LIST AF, SPIER CM, CLINE A, et al. Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype. Br J Haematol 1991: 78: 28-34.
25. ROTHENBERG M, LING V Multidrug resistance: molecular biology and clinical relevance. J Natl Cancer Inst 1989: 81: 907-910.
26. DRASH D, ZHAO S, ANDREEFF M. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 1992: 80: 2729-2734.
27. SGHINKEL A, SMIT J, BORST P. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994: 77: 491-502.